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Whole Exome Sequencing 
Identifies Frequent Somatic 
Mutations in Cell-Cell Adhesion 
Genes in Chinese Patients with 
Lung Squamous Cell Carcinoma
Chenguang Li1,2,†,*, Zhibo Gao3,*, Fei Li5,*, Xiangchun Li3,14,*, Yihua Sun1,2,*, 
Mengyun Wang2,4, Dan Li3, Rui Wang1,2, Fuming Li5, Rong Fang5, Yunjian Pan1,2, 
Xiaoyang Luo1,2, Jing He2,4, Liangtao Zheng3, Jufeng Xia5, Lixin Qiu2,4,6, Jun He3, 
Ting Ye1,2, Ruoxin Zhang2,4, Minghui He3, Meiling Zhu2,4, Haichuan Hu1,2, Tingyan Shi2,4, 
Xiaoyan Zhou2,7, Menghong Sun2,7, Shilin Tian3, Yong Zhou3, Qiaoxiu Wang3, 
Longyun Chen3, Guangliang Yin3, Jingya Lu3, Renhua Wu3, Guangwu Guo3, Yingrui Li3, 
Xueda Hu3, Lin Li3, Asan3, Qin Wang3, Ye Yin3, Qiang Feng3, Bin Wang3, Hang Wang3, 
Mingbang Wang3, Xiaonan Yang13, Xiuqing Zhang3, Huanming Yang3, Li Jin8, Cun-Yu Wang9, 
Hongbin Ji5, Haiquan Chen1,2, Jun Wang3,11,12 & Qingyi Wei4,10
Lung squamous cell carcinoma (SQCC) accounts for about 30% of all lung cancer cases. 
Understanding of mutational landscape for this subtype of lung cancer in Chinese patients is 
currently limited. We performed whole exome sequencing in samples from 100 patients with lung 
SQCCs to search for somatic mutations and the subsequent target capture sequencing in another 
98 samples for validation. We identified 20 significantly mutated genes, including TP53, CDH10, 
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NFE2L2 and PTEN. Pathways with frequently mutated genes included those of cell-cell adhesion/
Wnt/Hippo in 76%, oxidative stress response in 21%, and phosphatidylinositol-3-OH kinase in 36% of 
the tested tumor samples. Mutations of Chromatin regulatory factor genes were identified at a lower 
frequency. In functional assays, we observed that knockdown of CDH10 promoted cell proliferation, 
soft-agar colony formation, cell migration and cell invasion, and overexpression of CDH10 inhibited 
cell proliferation. This mutational landscape of lung SQCC in Chinese patients improves our current 
understanding of lung carcinogenesis, early diagnosis and personalized therapy.
Lung cancer remains the leading cause of cancer-related death worldwide1. Adenocarcinoma and squa-
mous cell carcinoma are two major subtypes of non-small cell lung cancer (NSCLC), which accounts 
for nearly 85% of all lung cancer cases, with a 5-year survival rate as low as 16%2. Novel drugs targeting 
the ‘driver’ mutations (e.g., EGFR tyrosine kinase mutations and ALK fusions) have led to prolonged 
survival and better quality of life for patients with lung adenocarcinoma3, in contrast to limited benefits 
for lung squamous cell carcinoma (SQCC), because current knowledge on lung SQCC tumorigenesis is 
still limited, especially in Chinese patients.
Previous studies have identified several mutated genes in lung SQCCs, such as TP53, EPHA2, NFE2L2, 
AKT1, LKB1, PTEN and ERBB24–9, as well as copy number gains of SOX2, FGFR1 and PDGFRA10–12, 
which have served as candidate driver genes for targeted therapy. Recent next-generation sequencing 
studies have showed a comprehensive genomic landscape of lung SQCCs in both Caucasian and Korean 
patients13,14. Frequently altered genes identified in these studies included TP53, NFE2L2, KEAP1, CUL3, 
and CSMD3. Nevertheless, the mutational landscape shown in these studies doesn’t explain all lung SQCC 
cases, and functional study on key mutated genes and pathways in lung SQCC is absent. Furthermore, 
no studies of genomic landscape of lung SQCCs in Chinese patients have reported to date. Therefore, 
additional evidence from genomic level sequencing and functional studies of lung SQCCs is needed.
In the present study, we searched for somatic mutations comprehensively in 198 Chinese lung SQCC 
patients, of which 100 cases undergone initial whole exome sequencing as a discovery cohort and an 
additional 98 cases for target capture sequencing as a prevalence cohort of independent samples. We 
aimed to uncover the genomic landscape and to find the key mutated genes for lung SQCCs in Chinese 
patients.
Results
Samples and clinical data. We initially screened by the whole exome sequencing of genomic DNA 
from tumors and paired normal lung tissues of 100 patients with untreated stage I-III lung SQCC as a 
discovery cohort (Supplementary Table 1) and followed by the target capture sequencing of an additional 
98 paired samples as a prevalence cohort (Supplementary Table 2). In the target capture sequencing, we 
focused on significantly mutated and potentially important functional genes observed in the discovery 
cohort. Overall, 87.9% (174/198) of the patients had a history of smoking, similar to those found in stud-
ies of Caucasian population13. We isolated and measured genomic DNA by the standard quality-control 
methods.
Gene mutational status in lung SQCCs. We generated reads with the Illumina HiSeq 2000 platform 
(Illumina Inc, San Diego, CA) and aligned them against the reference human genome (hg18). We found 
that 98.71% of the target regions were represented by at least one uniquely mapped read in both paired 
normal and tumor tissues, with a corresponding average sequencing depth of 48.2-fold and 49.4-fold in 
the exome sequencing, respectively. In addition, over 87.3% and 87.0% of the target regions for normal 
and tumor tissues, respectively, were covered sufficiently for confident variant calling (defined as ≥10X). 
Added by target capture sequencing, the sequencing depth in the target regions reached 100X. The mean 
and median mutation rate was 4.40 and 4.33 mutations per Mb (range, 0.04 to 11.64), respectively.
We used several rigorous bioinformatics approaches to identify reliable somatic mutations. To elim-
inate germline variants reported previously, we filtered our sequence data through the database of 
dbSNP132 and the 1000 Genome Project. In the discovery cohort, we identified a total of 11,979 somatic 
substitutions, including 2,287 synonymous, 8,004 missense, 634 nonsense and 18 stop-loss mutations, 
505 splice-site changes and 4,971 mutations in UTR, intronic and intergenic regions, in addition to 134 
small coding insertions or deletions (indels) (data file 1–2). The mutation spectrum of substitutions 
was dominated by C:G > A:T tranversions (31%), followed by C:G >T:A transitions (26%) that are most 
likely to be smoking specific15. Then, we performed validation for 621 somatic substitutions and all of 
the 134 coding indels. We confirmed 560 (90.2%) somatic substitutions and 79 (79%, out of 100 samples 
successfully sequenced) somatic indels by Sanger sequencing (data file 3–4). To further validate these 
findings, we performed the target capture sequencing in another independent 98 pairs of samples from 
patients with lung SQCCs as a prevalence cohort with a 100X sequencing depth, targeting on signifi-
cantly mutated and potentially important genes detected in the discovery cohort (data file 5–7).
We screened for the significantly mutated genes (SMGs) by MutSigCV16. As a result, we identified 
6 significantly mutated genes including TP53, NFE2L2, PTEN, KEAP1, FBXW7 and TMPRSS13 with a 
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false discovery rate (FDR) Q-value < 0.1. To identify key genes that would be missed by MutSigCV, we 
employed an algorithm present below by focusing only on cancer related genes (see Methods). Finally, 
we identified 20 SMGs from the exome and target capture sequencing data of 198 lung SQCC samples 
(Fig. 1). Seven of the 20 genes have been previously reported to be mutated in lung SQCCs, which are 
TP534,17,18, KEAP113,14,19, NEF2L26,13,20, PTEN14, KRAS13, PIK3CA13,14 and CDH1021. The tumor-normal 
lung mRNA expression levels of these 20 genes were queried from the TCGA Pan-Cancer dataset22 
(Supplementary Fig. 1). Of these significantly mutated genes, CDH10 attracted us because of the high 
Q-scores and potential functions. Mutations in the pair of CDH10 and CTNNA2 (P = 0.002) or KEAP1 
and NFE2L2 (P = 0.026) were mutually exclusive, indicating a functional interaction that is involved in 
lung tumorigenesis (Fig. 2a–c). Mutations in CDH10 were largely distributed throughout the entire gene 
allele, without recurrent mutation sites or specific localized areas (Fig. 2d).
CDH10 potentially plays a tumor-suppressor role in lung SQCC. Several lines of evidence suggest 
that CDH10 potentially play a tumor-suppressor role. Of the 41 mutations identified in the 198 samples 
analyzed (20 in the discovery cohort and 21 in the prevalence cohort), four were predicted to be inactivat-
ing mutations (three nonsense and one splice-site mutation) (Fig. 2d). Seven of 33 samples with CDH10 
mutations had two or three independent mutations, presumably inactivating two alleles. In the sample 
1019LC, for example, we identified two nonsynonymous mutations (i.e. NM_006727:c.C2059T:p.R687W 
and NM_006727:c.T1883C:p.V628A), and the first was predicted to affect a cadherin domain. Intriguingly, 
there were 38 reads/read-pairs that spanned across both mutations, of which 7 supported the first muta-
tion (i.e. NM_006727:c.C2059T:p.R687W), while 11 supported the second (i.e. NM_006727:c.T1883C:p.
V628A), but none of these 7 or 11 reads/read-pairs supported both (Supplementary Fig. 2). Therefore, 
it is likely that these two mutations may target each of the two alleles separately, leading to the bi-allelic 
inactivation of CDH10, which meets the requirement of the “two-hits” model of a tumor-suppressor 
gene. CDH10 has been reported to be mainly expressed in human brain and prostate23, we also compared 
CDH10 expression levels among lung, brain and prostate tissues (Supplementary Fig. 3–4). Western-blot 
analysis and qualitative PCR confirmed that that CDH10 is expressed in the lung at a lower level than in 
brain and prostate, which is consistent with previously published studies16. In the functional assays using 
two lung cancer cell lines with high CDH10 expression (NCI-H522 and NCI-H1373) (Supplementary 
Fig. 5 a,b), CDH10 silencing using different shRNAs consistently resulted in a significant increase in 
cell proliferation (Supplementary Fig. 6 a,f) and soft-agar colony formation (Supplementary Fig. 6 g,h). 
Figure 1. Significantly mutated genes in lung SQCC. Significantly mutated genes (Qvalue < 0.1) identified 
by exome and target capture sequencing of 198 lung SQCCs are listed vertically by Q-value. The percentage 
of individuals with mutations of each gene is shown on the left. Samples displayed as columns and the 
overall number of mutations is plotted at the top. SMGs identified by both algorithms are marked with red 
font color. Samples screened by whole exome sequencing are marked with green font color, samples screened 
by target capture sequencing are marked with orange font color. Syn., synonymous; WES, whole exome 
sequencing; TCS, target capture sequencing.
www.nature.com/scientificreports/
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We further found that CDH10 silencing also promoted cell migration (Supplementary Fig. 6 i,j) and 
cell invasion in matrigel culture (Supplementary Fig. 6 k,l). Knockdown of CDH10 in another cell line 
(NCI-1437) also significantly increased cell proliferation (Supplementary Fig. 5 c,d). Overexpression of 
CDH10 significantly inhibited cell proliferation in wild-type mouse embryonic fibroblasts (MEFs) and 
mouse lung cancer cell line L793 (Supplementary Fig. 7). Collectively, these functional studies further 
demonstrated that CDH10 might serve as a tumor suppressor in lung carcinogenesis.
Frequently mutated pathways in lung SQCC. Frequent somatic mutations in specific biological 
pathways indicate their unique roles in tumorigenesis and progression. To identify key mutated pathways 
of lung SQCCs, we firstly screened mutated genes through published papers on NSCLC mutational spec-
trum; secondly, frequently and potentially important mutated genes were searched in KEGG and Cell 
Signaling pathway database manually. In the present study, except for the well-studied TP53 mutations, 
other pathways with frequently mutated genes included those of cell-cell adhesion/Wnt/Hippo in 76.8%, 
oxidative stress response in 21.2%, and phosphatidylinositol-3-OH kinase in 36.9% of the tested tumors. 
Most remarkably, genes involved in the cell-cell adhesion/Wnt/Hippo signaling pathway were frequently 
affected by somatic mutations (Fig.  3a). We observed somatic mutations of several cadherin genes, of 
which CDH10 (14.6%) was the most frequently mutated, and other mutated cadherin genes included 
CDH18 (8%), FAT4 (7%) and PCDH15 (8.6%). Overall, 69.2% of samples had non-silent mutations of the 
cadherin superfamily genes (data file 8). It is known that α -catenin is a binding partner of the cadher-
ins encoded by CTNNA1, CTNNA2 and CTNNA3, and the latter two genes were mutated in 11.1% and 
3% of the tested samples, respectively. Furthermore, α -catenin links cell-cell junction genes to the Wnt 
and Hippo/YAP signaling pathway, modulating cell-cell adhesion and contact inhibition. Other mutated 
genes in this pathway included CRB1, LATS1/2 and YAP1, suggesting that alteration of the cell-cell adhe-
sion/Wnt/Hippo signaling pathway may play the vital role in lung SQCC.
The oxidative stress response pathway protects cells against oxidative and xenobiotic damage, and 
genetic alterations of NFE2L2 and KEAP1 have been previously reported in NSCLC13,24,25. In the present 
study, NFE2L2 and KEAP1 were mutually exclusively mutated in 14.6% and 6.6% of the tested sam-
ples (P = 0.026), respectively, accounting for 21.2% of the 198 lung SQCC samples (Fig. 3b,c). NFE2L2 
encodes a transcriptional factor that induces cytoprotective proteins upon oxidative damage, and the 
cellular NFE2L2 level is regulated by KEAP126. All of the eight mutations identified in NFE2L2 in the 
present study were in exon 2, which is the key region that interacts with KEAP120. These findings con-
firmed previous studies that NFE2L2 and KEAP1 were frequently mutated and played important roles in 
Figure 2. Mutually exclusive/concurrent mutated genes and somatic mutations in CDH10 in lung 
SQCCs. (a) Concurrent and mutually exclusive mutations observed in frequently mutated genes in lung 
SQCCs. For each gene (row), tumors (columns) with or without mutations are labeled in red or blue, 
respectively. (b–c) Totally mutual exclusive (no mutations from the two genes in one sample) in several pairs 
of gene, such as KEAP1 and NFE2L2, CDH10 and CTNNA2, are shown. (d) Somatic mutations in CDH10. 
The types and relative positions of somatic mutations are shown in the transcripts of CDH10 using the 
following symbols: red stars, nonsense mutations; bullets, missense mutations; blue diamonds, mutations at 
splice sites. Domains and motifs in each encoded protein product are also indicated.
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lung SQCCs13,20. Mutations of genes in the phosphatidylinositol-3-OH kinase pathway have been previ-
ously reported in NSCLC, especially in lung adenocarcinoma13,27. In the present study, 36.9% of samples 
harbored at least one non-silent mutation in genes of this pathway (Fig.  3c). Although the receptor 
kinase genes were much less frequently mutated in lung SQCC than in lung adenocarcinoma, PIK3CA 
and PTEN were commonly altered in lung SQCCs in the present study.
Somatic mutations affected chromatin regulatory factors in lung SQCCs. The chromatin reg-
ulatory factors referred to those proteins that regulate chromatin structure, thus maintain genome integ-
rity and regulate gene expression28. Genetic alteration of these group of genes have been reported in 
various types of cancer, mainly including renal cell carcinoma29, bladder cancer30, endometrium31, breast 
Figure 3. Significantly mutated pathways in lung SQCC. Somatic mutations in lung SQCC frequently 
occurred in genes of the (a) Cell-Cell adhesion/Wnt/Hippo/YAP, (b) Oxidative stress response, (c) PI3K/
RTK/RAS signaling pathways. Oncogenes are indicated in pink to red and tumor suppressor proteins are 
shown in light to dark blue. The darkness of the colors is positively correlated to the percentage of tumors 
with genetic alterations. The frequency of genetic alterations for each of these pathway members in 198 
tumors is indicated.
www.nature.com/scientificreports/
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cancer32 and so on. We annotated the mutated genes in our study to the list of likely driver chromatin 
regulatory genes reported previously28, and found a 27.3% overall mutation rate of these genes, which 
was also largely mutual exclusive (Supplementary Fig. 8a). Interestingly, we found a trend of complete 
mutual exclusive correlation between these genes when they were gathered as SWI/SNF and PRC pro-
tein complexes (Supplementary Fig. 8b,c), with an overall mutation rate of 13.6% and 7.1%. These above 
results suggest that chromatin regulatory genes are affected by somatic mutations in lung SQCCs, largely 
in the form of protein complexes rather than individual genes.
Clinical-pathological and mutual association analyses of frequently mutated genes. Genes 
that play key roles in tumor initiation and progression often exhibit strong associations with 
clinical-pathological characteristics, in a mutually exclusive or concurrent relationship with other 
mutated genes. Therefore, we performed additional analyses to further uncover potential oncogenes 
and tumor-suppressor genes in lung SQCCs. Pairs of mutually exclusive genes included NFE2L2 and 
KEAP1 (P = 0.026), CTNNA2 and CDH10 (P = 0.002), CTNNA2 and C6 (P = 0.023), ZEB2 and KIF2B 
(P = 0.033), CRB1 and NFE2L2 (P = 0.012) and other pairs of genes (Fig. 2a–c, data file 9).
In the present study, we found that mutations in CSMD3 were associated with early TNM stage 
(P = 0.001) and significantly less frequent in N2 than N0 and N1 tumors (P = 0.007). As a gene with 
very long coding region, CSMD3 mutations were frequently identified but not significantly mutated 
than background mutation. In a previous study, loss of CSMD3 resulted in increased proliferation of 
airway epithelial cells33. As a potential candidate tumor suppressor, loss of heterozygosity or homozygous 
deletions may occur in genomic area of CSMD334,35, however, we did not find loss of copy number in 
genomic regions of CSMD3 in tumor samples compared with normal lung samples (data file 10). Based 
on current evidences, the function of CSMD3 gene in lung carcinogenesis needs further validation. We 
also found that mutations in PTEN were associated with early TNM stages (P = 0.02) and significantly 
less frequent in N2 tumors (P = 0.002) (Supplementary Fig. 9). Finally, we identified a panel of genes 
whose frequent mutations were detected only in smokers, including NFE2L2, MAGEC1, NLRP3 and 
FAM5C. As most lung SQCC cases occur in patients with smoking history, those mutated genes which 
were only found in smokers in this study need further validation with lager number of patients. Although 
smokers and non-smokers did share some mutations of the same genes, we did not find any of other 
frequently mutated genes that were exclusively found in non-smokers.
Discussion
As described in previously published sequencing studies of lung SQCC of Caucasian patients13,33, the 
present study showed similar characteristics of mutations in Chinese patients, such as high mutation 
rates of TP53, CSMD3 and genes in the oxidative stress response and PI3K pathways, but the pres-
ent study also uncovered some novel genes (such as the cadherin family genes) and pathways (such as 
the cell-cell adhesion/Wnt/Hippo pathway), indicating that there are commonly altered functions in 
cell-cell adhesion, contact inhibition, oxidative stress response and apoptotic signaling in lung SQCC 
tumorigenesis.
We screened for the mutation frequency of 20 SMGs across TCGA data, which included both 11 
other cancer types and lung squamous cell carcinoma (Fig.  4). Both TCGA and our study on lung 
SQCC showed high mutation frequencies of TP53, NFE2L2 and PTEN, indicating similar molecular 
events in squamous carcinogenesis. CDH10 was found to be frequently mutated in both lung squamous 
cell carcinoma and adenocarcinoma than other cancer types, which further indicated the importance 
of CDH10 mutations in NSCLC development. Compared with the 178 and 104 lung SQCCs samples 
from Caucasian patients13 and Korean patients14, we found similar main SMGs including TP53, KEAP1, 
NFE2L2 and PTEN (Supplementary Fig. 10) in Chinese patients. Interestingly, some of those frequently 
mutated genes identified in the TCGA lung SQCC study were not found in the present study. For exam-
ple, inactivation of CDKN2A caused by somatic mutations was seldom observed in the present and 
Korean lung SQCC studies. It is possible that other mechanisms, such as methylation and homozygous 
deletion, may contribute to the loss of CDKN2A functions in Asian lung SQCC. The rare NOTCH1 trun-
cating mutations observed in the present study indicates that squamous differentiation genes may not 
play key roles in lung SQCC of Chinese patients, different from those in SQCCs of the lung and head and 
neck reported for Caucasian patients13,36. MLL2 was identified as a SMG with a mutation rate as high as 
20% in Caucasian and Korean patients. However, MLL2 mutations were not found in the present study. 
Other frequently mutated genes found in the Korean study like CHD7, NF1 and NOTCH were much 
rarer in our study. On the other hand, frequently mutated cell-cell adhesion genes, which gone through 
target-capture sequencing in our study, were not shown in the Korean study. Our study indicated that 
cell-cell adhesion gene on the whole are frequently mutated and disordered in lung SQCCs of Chinese 
patients. Those above differences in significantly and frequently mutated genes among different cohort of 
patients offer additional evidences of lung SQCC tumorigenesis, which is worth of further investigation.
We also compiled the so-called cancer druggable genes according to DrugBank, NCI, PharmGKB, 
as well as curated from published papers, which led to 389 drugs with diverse targets, and we selected 
potentially therapeutic targets through the exome data from the discovery cohort of 100 lung SQCCs. 
Somatic mutations that had medium or high effects as determined by mutation accessor were calculated, 
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if they could be targeted by one of these 389 drugs. Finally, we identified 63 potential druggable cases, 
indicating that 63% of lung SQCC patients could potentially receive target therapies (data file 11).
The cadherin-catenin complex is the major player involved in the formation of cell-cell adherens junc-
tions and important for maintaining cell polarity and tissue integrity, which potentially limits cell move-
ment and proliferation37. The cadherin genes are characterized by multiple repeats of the cadherin motif 
in their extracellular domains that are involved in the Ca2+ binding, whereas their cytoplasmic domains 
significantly diverge among these members. Growing lines of evidence suggest that cadherins may play 
critical roles in control of the proliferative or oncogenic signaling, including the Wnt/β -catenin, Ras/
MAPK and Hippo/YAP pathways (Fig. 3a, Supplementary Fig. 11)37,38. For example, α -catenin has two 
major subtypes: α E-catenin (encoded by CTNNA1) and α N-catenin (encoded by CTNNA2). α -catenin 
maintains structure integrity of the epithelium through interacting with cadherin-α -catenin complexes 
and cytoskeleton. While CTNNA2 was less studied, over-expression of α N-catenin, like α E-catenin, in 
the PC-9 lung carcinoma cell line was able to restore cell-cell adhesion and epithelial morphology39. 
Recently, α E-catenin was found to be the key molecule in the Hippo signaling pathway, controlling cell 
proliferation by interacting with YAP138,40,41. Abnormal activation of YAP due to loss of α E-catenin led to 
squamous cell carcinoma-like tumors in the mouse skin38. The integrity of the cadherin-catenin complex 
is negatively regulated by phosphorylation of β -catenin, receptor tyrosine kinases (RTKs) and cytoplas-
mic tyrosine kinases, which leads to dissociation of the cadherin-catenin complex. The Wnt signaling 
acts as a positive regulator of β -catenin by inhibiting β -catenin degradation. Further, cadherin may acts 
as a negative regulator of β -catenin by binding to β -catenin at the cell surface and sequesters it from 
the nucleus. Taken together, our results suggest that among other unknown mechanisms, dysregulation 
of the cadherin-catenin complex caused by somatic mutations may promote lung SQCC formation by 
modulating multiple signaling pathways.
In summary, we identified both the well-known and unreported somatic mutations in lung SQCCs by 
using the exome sequencing of 100 followed by target capture sequencing of 98 paired samples of tumors 
and their adjacent normal tissues in Chinese patients. We uncovered a high somatic mutation frequency 
of the cell-cell adhesion/Wnt/Hippo pathway genes in lung SQCC and demonstrated that CDH10 exerted 
tumor suppressor role. Our results illustrated the landscape of the mutation spectrum of lung SQCC in 
Chinese patients and provided valuable candidate genes for further investigations.
Methods
Tissue collection and DNA isolation. A total of 198 lung SQCC tissue samples and paired normal 
lung tissue samples were collected between Oct, 2007 and Dec, 2011 at Fudan University Shanghai Cancer 
Center, Shanghai, China. Clinical data were collected in the perioperative period (Supplementary Table 
Figure 4. Mutation diversity of SMGs in Chinese lung SQCCs and other cancer types from TCGA data. 
Percentages of samples mutated in each cancer types and Pan-Cancer are shown, and the highest percentage 
in each gene is shown in bold. BLCA, bladder urothelial carcinoma; BRCA, breast adenocarcinoma; 
COAD,READ, colon and rectal carcinoma; GBM, glioblastomamultiforme; HNSC, head and neck squamous 
cell carcinoma; KIRC, kidney renal clear cell carcinoma; LAML, acute myeloid leukaemia; OV, ovarian 
serous carcinoma; UCEC, uterine corpus endometrial carcinoma; LUAD, lung adenocarcinoma; LUSC, lung 
squamous cell carcinoma (TCGA study); LUSQCC, lung squamous cell carcinoma (the present study).
www.nature.com/scientificreports/
8Scientific RepoRts | 5:14237 | DOi: 10.1038/srep14237
1–2). After initial 100 paired tumor-normal lung samples were screened by the whole exome sequencing 
as a discovery cohort, and an independent group of additional 98 paired tumor-normal lung samples 
underwent the target-capture sequencing as a prevalence cohort to validate initial important findings. 
All patients provided a written consent form before recruitment into the study. This study was approved 
by the Ethics Review Board of Fudan University Shanghai Cancer Center and the methods were carried 
out in accordance with the approved guidelines. Fresh surgical samples were snap-frozen and stored in 
liquid nitrogen upon resection until use. Each tumor sample was determined as a primary lung SQCC 
by pathologists, with a minimum of 70% of tumor cellularity, and all patients did not receive neoadjuvant 
chemotherapy. DNA of tumors and paired normal lung tissue was isolated by using standard protocols 
of QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). A total amount of 5 μ g DNA of each sample 
was used for the exon capture. The quality of genomic DNA was examined by both spectrophotometer 
(Nanodrop, Thermo Fisher Scientific Inc.) and gel-electrophotometric method.
Illumina-based whole-exome sequencing. Genomic DNA from tumors and normal tissues was 
fragmented and hybridized to commercially available capture arrays for enrichment. The whole exome 
capture procedure was performed with Agilent’s SureSelect Human All Exon Kit protocol (Agilent 
SureSelect Human All Exon Kit 38MB). Resulting DNA libraries with an insert size of 200 bp on average 
were sequenced using the 90-bp paired-end technology on Illumina Hiseq 2000. Real-time image anal-
ysis and base calling were performed by Hiseq Control Software version 1.1.37 and Real Time Analysis 
version 1.7.45 using standard parameters, respectively.
Reads mapping and mutations detection. After removing reads containing sequencing adapt-
ers and low-quality reads with more than five unknown bases, the high quality reads were aligned to 
the NCBI human reference genome (hg18) using BWA42 (v0.5.9) with the default parameters. Picard43 
(v1.54) was employed to mark duplicates and followed by Genome Analysis Toolkit44 (v1.0.6076) (GATK 
IndelRealigner) to improve alignment accuracy.
Somatic SNVs were detected by VarScan2.2.545 (samtools (v0.1.18) mpileup –Q 0 && VarScan2.2.5 
somatic --min-coverage 10 --min-coverage-normal 10 --min-coverage-tumor 10 --min-var-freq 0.1 
--min-avg-qual 0). Somatic indels were predicted with GATK SomaticIndelDetector with default param-
eters. All high confident mutations were obtained using in house pipeline coupled with visual inspection, 
then annotated with ANNOVAR46 (released time 2011-10-02).
Validation of somatic mutations by Sanger sequencing. To validate somatic SNVs and indels 
with Sanger sequencing, PCR primers designed for the putative somatic variants were used to amplify the 
DNA from the tumors first. If the mutations were confirmed in the tumors, the same primer pairs were 
used to amplify the DNA of normal lung tissues from the same subjects to determine somatic status of 
the mutations. Detailed information of validation is shown in Data file 3–4.
Illumina-based target-capture sequencing. After the whole exome sequencing of 100 pairs of 
samples as a discovery cohort, we identified significantly mutated genes by NS:S statistics as described 
previously27,47. We also observed a number of potentially important genes that were frequently mutated 
in lung SQCCs, such as the cadherin superfamily genes. To validate these important findings in a large 
number of independent samples as a prevalence cohort, we ordered the Target Capture Array from 
Angilent corporation, targeting 193 genes (Data file 7) identified from the discovery cohort.
Identification of significantly mutated genes. We first applied MutSigCV16 to identify signifi-
cantly mutated genes (SMGs) in the exome and target capture sequencing cohorts of 198 SQCCs, which 
produced 6 SMGs (i.e. TP53, NFE2L2, PTEN, KEAP1, FBXW7 and TMPRSS13) with q-value < 0.1, this 
probably due to relatively small number of mutations and large number of genes (18,862 in total) being 
used in MutSigCV, leading to many multiple hypothesis test corrections. To identify key genes that 
would be missed by MutSigCV, we employed an algorithm present below by focusing only on cancer 
related genes. We began by obtaining background mutation rates for each category (i.e. C = {*CpG- > T, 
*Cp(A/C/T)- > T, A- > G, transver, and null + indel}) from MutSigCV1. For the ease of description, the 
background mutation rates for these five categories are denoted as r = {r*CpG-> T, r*Cp(A/C/T)->T, rA->G, rtransver, 
rnull+indel}, the number of bases for each category in gene denoted as ng = {ng.*CpG->T, ng.*Cp(A/C/T)->T, ng.A->G, 
ng.transver, ng.null+indel}. In this case, the expected number of somatic mutations in gene g was calculated as:
∑λ =
( )∈
⁎n r
1g C C
g
The p-value of observing Xg ≥ K somatic mutations in gene g given the expected mutation count λg is:
( )
λ
!
≥ = ( )
λ−
P X K g
e
K 2g
g
k g
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The Benjamini Hochberg method of false discovery rate control (FDR-BH) was used to convert 
p-values into q-values. This algorithm produced 20 SMGs.
Functional study of CDH10 in lung cancer cell lines. Cell culture. Human lung cancer cell lines 
NCI-H522 and NCI-H1373 were purchased from ATCC (American Tissue Culture Collection, the 
Global Bioresource Center) and used for functional studies within six months after thaw from liquid 
nitrogen tank. All cells were cultured in DMEM medium (Hyclone) supplemented with 8% fetal bovine 
serum (FBS) (Biochrom AG, Germany) and antibiotics (100 U/ml streptomycin and 100 μ g/ml penicil-
lin) (Invitrogen, USA). The human cell line HEK-293T cells were maintained in DMEM (Hyclone) sup-
plemented with 8% fetal bovine serum (FBS) and antibiotics. L793 cell line is a mouse cell line derived 
from lung SQCC tumor of KrasG12D/Lkb1L/L (Kras/Lkb1) mice48.
Plasmids and lentivirus package. The human CDH10 sequence was amplified from NCI-H522 cDNA 
using primers:
 5′ -CGGAATTCGCCACCATGGACTACAAGGACGACGATGACAAGACAATACATCAATTTTT 
GCTACTGTTTC-3′ (fo rw ard, EcoRI-flag-F)
5′ -CGGGATCCTTAAGAGTCTTTGTCACTTTCCCCAC-3′ (reverse, BamHI-R)
Amplicon was inserted into pCDH-Puro.
The shRNAs towards human CDH10 were cloned into pLKO.1 (Addgene). The target
sequences are:
shCDH10 -1:
5′ -CGGCGAGATATTATTCCAGAA-3′
shCDH10 -2:
5′ -CGGTACTGATATGTTTGACAT-3′
RT-PCR and real-time PCR. We extracted the total RNA by using the Trizol reagent (Invitrogen) 
according to the manufacturer’s instructions and reverse-transcribed into cDNA (Ferments).
The cDNAs were then used for either regular PCR or real-time PCR on a 7500 Fast Real-Time PCR 
System (Applied Biosystems) using the SYBR-Green Master PCR mix (Invitrogen). GAPDH served as 
the internal control.
Primers used were:
Human CDH10: 5′-CGCCAGAGTCATTTACAGCA-3′ (forward) and
5′ -ATGTCTTTGGCCTGGATGAC-3′ (reverse);
Human GAPDH: 5′-AGGTGAAGGTCGGAGTCAAC-3′ (forward) and
5′ -AGTTGAGGTCAATGAAGGGG-3′ (reverse).
The MTT assay. Cells were plated in 96-well plates (Nest) at a density of 2500 cells per well and cell 
viabilities were detected at indicated time points. At different time points (Day1–Day5), 20 μ l of MTT 
(Sigma) solution (5 mg/ml) was added into each well. Cells were incubated at 37 °C for 4 h. Then the 
medium was removed and 100 μ l DMSO was added to each well to solubilize the formazan crystals. 
Absorbance was measured at dual wavelength modes (595 nm and 650 nm) using a Microplate Reader 
(Thermo, MULTISKAN MK3, USA). The values were normalized by defining the value of day1 as 1.
Soft agar assay. Cells were suspended on a top layer of DMEM containing 8% FBS and 0.4% agar 
(Gibco/Invitrogen) in 6-well plates in triplicate and plated on a bottom layer of DMEM containing 8% 
FBS and 1% base agar. Colonies were photographed and stained with 0.005% crystal violet for 1 hr after 
2-week culture and then colonies were counted and analyzed by Quantity One.
Wound healing assay. Cells at 100% confluence were starved in the serum-free medium for over 12 hours 
dependent on different cell lines. Cells were then lightly and quickly scratched with a pipette tip. The cell 
migration kinetics were closely monitored and photographed using a light microscope (Leica).
Three dimensional cell culture. Cells were seeded in the medium contain 2% matrigel (BD) on the top 
of another layer of solidified matrigel. Cells were then cultured at 37 °C incubators and monitored for 
the appearing morphologic changes in 1~2 weeks. Photos were taken using a light microscope (Leica).
Immunohistochemistry staining and immunoblotting analyses. Histology immunohistochemical and 
immunoblotting analyses were performed according to standard protocols, as previously described49. 
CDH10 antibodies used in these assays were bought from Abgent (Catalog: AP1482c) and LifeSpan 
(Catalog: LS-C138484) company.
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